Clinical studies investigating the refinement of AAT augmentation or aiming to investigate new therapeutic applications of AAT in human diseases, including diabetes type-1 [25] and graft-versus-host disease [26], require measurement of the AAT activity and AAT protein concentrations in biological specimens. This evidence concerns the gene SERPINA1 and type 1 diabetes mellitus.